Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Abstract

Metastatic melanoma is notoriously resistant to chemotherapy and radiotherapy regimens. The prospect for newly diagnosed metastatic melanoma patients is grim, with a median survival of less than 1 year. Currently, the only therapies resulting in long-term disease-free intervals, high-dose interleukin-2 (IL-2) and more recently anti-CTLA-4, work through… (More)
DOI: 10.1053/j.seminoncol.2012.01.006

Topics

Cite this paper

@article{Bernatchez2012AdvancesIT, title={Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.}, author={Chantale Bernatchez and Laszlo G. Radvanyi and Patrick Hwu}, journal={Seminars in oncology}, year={2012}, volume={39 2}, pages={215-26} }